Immunopathology — MCQs

Immunopathology Indian Medical PG Practice Questions and MCQs

Question 151: MHC class III genes encode which of the following?

A. Complement component C3
B. Tumor necrosis factor (Correct Answer)
C. Interleukin 2
D. Beta 2 microglobulin

Explanation: The Major Histocompatibility Complex (MHC) is a large genetic locus on **chromosome 6p** in humans. While MHC Class I and II are primarily involved in antigen presentation, the **MHC Class III** region is unique because its gene products do not present antigens but instead play critical roles in the innate immune response and inflammation. ### Explanation of the Correct Answer **B. Tumor necrosis factor (TNF):** The MHC Class III region encodes several non-HLA proteins, most notably cytokines like **TNF-α** and **Lymphotoxin (TNF-β)**. These proteins are potent mediators of inflammation and immune regulation [1]. ### Explanation of Incorrect Options * **A. Complement component C3:** While MHC Class III encodes several complement components (**C2, C4A, C4B, and Factor B**), it does **not** encode C3. C3 is encoded by a gene on chromosome 19. The functions of the complement system are mediated by breakdown products of C3 [1]. * **C. Interleukin 2:** IL-2 is a cytokine primarily produced by T-cells and is encoded by a gene on chromosome 4. * **D. Beta 2 microglobulin:** This is the invariant light chain of the MHC Class I molecule. Crucially, while the heavy chain of MHC Class I is encoded on chromosome 6, $\beta_2$-microglobulin is encoded on **chromosome 15**. ### High-Yield Clinical Pearls for NEET-PG * **MHC Class III Products:** Remember the mnemonic **"C2, C4, Factor B, and TNF."** It also includes Heat Shock Proteins (HSP). * **MHC Class I vs. II:** Class I (HLA-A, B, C) is found on all nucleated cells; Class II (HLA-DP, DQ, DR) is found only on Antigen Presenting Cells (APCs). * **Linkage Disequilibrium:** MHC Class III genes are often inherited together with specific Class I and II alleles, which is significant in autoimmune disease associations (e.g., SLE and C4 deficiency). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, pp. 97-99.

Question 152: Which of the following features distinguishes a Type 1 hypersensitivity reaction from a Type 2 hypersensitivity reaction?

A. Type 1 reaction is IgE mediated. (Correct Answer)
B. Type 1 reaction is complement mediated.
C. Type 1 reaction involves opsonization.
D. Type 2 reaction is IgE mediated.

Explanation: ### Explanation Hypersensitivity reactions are classified by the **Gell and Coombs system** based on the immune mechanism involved [2]. **Why Option A is Correct:** **Type 1 (Immediate) Hypersensitivity** is uniquely characterized by the production of **IgE antibodies** in response to specific antigens (allergens) [1], [3]. These IgE molecules bind to high-affinity Fc̅́RI receptors on **mast cells and basophils** [1]. Upon re-exposure, the allergen crosses-links the IgE, triggering degranulation and the release of vasoactive amines like histamine. **Why the Other Options are Incorrect:** * **Option B & C:** Complement activation and opsonization are hallmarks of **Type 2 (Antibody-mediated)** and **Type 3 (Immune complex-mediated)** reactions [2], [4]. In Type 2, IgG or IgM binds to cell surface antigens, leading to cell lysis via the Classical Complement pathway or phagocytosis via opsonization [2], [4]. * **Option D:** This is factually reversed. Type 2 reactions are mediated by **IgG or IgM**, not IgE [2]. **NEET-PG High-Yield Pearls:** * **Mnemonic (ACID):** **A**naphylactic (Type 1), **C**ytotoxic (Type 2), **I**mmune-Complex (Type 3), **D**elayed-type (Type 4). * **Biphasic Response:** Type 1 has an **Immediate phase** (minutes; histamine-driven) and a **Late-phase** (2–24 hours; eosinophil-driven via IL-5). * **Key Cytokines:** Th2 cells drive Type 1 reactions by secreting **IL-4** (stimulates IgE isotype switching) and **IL-5** (activates eosinophils) [1]. * **Examples:** Type 1 includes Anaphylaxis, Asthma, and Urticaria; Type 2 includes Myasthenia Gravis, Rheumatic Fever, and Erythroblastosis Fetalis [3], [4]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 210-211. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 208-210. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 171-172. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 214.

Question 153: HLA-DR4 is a marker of which disease?

A. Rheumatoid arthritis (Correct Answer)
B. Sarcoidosis
C. Sero-negative gouty arthritis
D. Psoriasis

Explanation: The association between Human Leukocyte Antigens (HLA) and specific diseases is a high-yield topic for NEET-PG. HLA-DR4 is a Class II MHC molecule strongly associated with **Rheumatoid Arthritis (RA)**. **1. Why Rheumatoid Arthritis is correct:** The "Shared Epitope" hypothesis explains that specific alleles of HLA-DRB1 (most notably **HLA-DR4** and DR1) contain a conserved sequence of amino acids [1]. This sequence facilitates the presentation of arthritogenic self-antigens (like citrullinated peptides) to T-cells, triggering the autoimmune inflammatory cascade characteristic of RA [1]. Patients with HLA-DR4 often exhibit more aggressive disease and higher titers of Rheumatoid Factor. **2. Why other options are incorrect:** * **Sarcoidosis:** While some HLA associations exist (like HLA-DRB1*03), there is no definitive link to HLA-DR4. Its pathogenesis is primarily related to non-caseating granulomatous inflammation of unknown etiology. * **Sero-negative Gouty Arthritis:** Gout is a metabolic/crystal-induced arthropathy (monosodium urate crystals) and is not primarily an HLA-linked autoimmune disease. * **Psoriasis:** This is classically associated with **HLA-Cw6**. When it progresses to Psoriatic Arthritis (a seronegative spondyloarthropathy), it is strongly linked to **HLA-B27** [2]. **Clinical Pearls for NEET-PG:** * **HLA-B27:** Associated with "PAIR" (Psoriatic arthritis, Ankylosing spondylitis, Inflammatory bowel disease, and Reactive arthritis) [2]. * **HLA-DR3:** Associated with SLE, Type 1 Diabetes Mellitus, and Graves' disease. * **HLA-DQ2/DQ8:** Associated with Celiac disease. * **Mnemonic for RA:** "Four (DR4) walls in a Rheum (Rheumatoid)." **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Bones, Joints, and Soft Tissue Tumors, pp. 1212-1214. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Bones, Joints, and Soft Tissue Tumors, pp. 1214-1215.

Question 154: Which of the following is an example of a Type II hypersensitivity reaction?

A. Blood transfusion reaction (Correct Answer)
B. Autoimmune hemolytic anemia
C. Allergic rhinitis (Hay Fever)
D. Post-streptococcal glomerulonephritis

Explanation: ### Explanation **Type II Hypersensitivity** is defined as **Antibody-Mediated Cytotoxicity** [4]. It occurs when IgG or IgM antibodies bind to antigens present on the surface of specific cells or tissues, leading to cell destruction via the complement system, opsonization (phagocytosis), or ADCC (Antibody-Dependent Cellular Cytotoxicity) [4]. **Why Option A is Correct:** **Blood transfusion reactions** (specifically acute hemolytic reactions) occur when recipient antibodies (e.g., anti-A or anti-B) bind to antigens on the donor’s red blood cells [1]. This triggers the complement cascade, leading to immediate intravascular hemolysis. This is a classic example of Type II hypersensitivity. **Analysis of Incorrect Options:** * **Option B (Autoimmune Hemolytic Anemia):** While this is *also* a Type II hypersensitivity reaction, in the context of this specific question format, Blood Transfusion Reaction is the most frequently cited "textbook" example for initial identification. *(Note: If this were a "Multiple Select" or "All except" question, B would also be considered mechanistically Type II).* [2] * **Option C (Allergic Rhinitis):** This is a **Type I (Immediate) Hypersensitivity** reaction mediated by IgE antibodies and mast cell degranulation. * **Option D (Post-streptococcal Glomerulonephritis):** This is a **Type III (Immune-Complex) Hypersensitivity** reaction, where antigen-antibody complexes circulate and deposit in the glomerular basement membrane. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Type II:** Remember the **3 "C"s**: **C**omplement-mediated lysis, **C**ell cytotoxicity (ADCC), and **C**ell dysfunction (e.g., Myasthenia Gravis/Graves' Disease) [3]. * **Direct Coombs Test:** Used to detect Type II reactions involving RBCs (like HDN or AIHA) [2]. * **Other Type II Examples:** Goodpasture syndrome, Pemphigus vulgaris, and Rheumatic fever. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 627-628. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 651-652. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 213-214. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 214.

Question 155: ABO incompatibility leads to which type of transplant rejection?

A. Hyperacute rejection (Correct Answer)
B. Acute rejection
C. Chronic rejection
D. None of the above

Explanation: **Explanation:** **Hyperacute rejection** is the correct answer because it occurs within minutes to hours of transplantation due to **pre-formed antibodies** in the recipient's serum. In the case of ABO incompatibility, the recipient possesses naturally occurring IgM antibodies (isohemagglutinins) against the donor's A or B antigens present on the vascular endothelium of the graft. This triggers a **Type II Hypersensitivity reaction**, leading to complement activation, endothelial damage, extensive thrombosis, and fibrinoid necrosis [1], resulting in the graft turning "cyanotic and mottled" [1] on the operating table. **Why other options are incorrect:** * **Acute Rejection:** This occurs days to weeks after transplant [1]. It is primarily mediated by T-cells (Type IV Hypersensitivity) or newly formed antibodies (Type II). It is not caused by pre-existing ABO antibodies. * **Chronic Rejection:** This occurs months to years post-transplant. It involves slow, progressive fibrosis and intimal thickening of graft vessels (accelerated atherosclerosis), driven by chronic cytokine release and low-grade inflammation. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Hyperacute rejection is characterized by **thrombotic microangiopathy** [1]. * **Prevention:** It is prevented by **cross-matching** (testing recipient serum against donor lymphocytes) and ABO blood grouping [2]. * **HLA Antigens:** While ABO is a major trigger, pre-formed antibodies against HLA antigens (from previous transfusions or pregnancies) can also cause hyperacute rejection. * **Morphology:** Look for "Fibrinoid necrosis" and "Neutrophilic infiltration" in the graft vasculature in exam vignettes [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 241-242. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 179-180.

Question 156: p-ANCA positivity is specific for which of the following conditions?

A. Polyarteritis nodosa
B. Wegener's granulomatosis (Correct Answer)
C. Henoch-Schonlein purpura
D. Churg-Strauss syndrome

Explanation: **Explanation:** The correct answer is **Wegener’s granulomatosis** (now known as Granulomatosis with Polyangiitis - GPA). **Understanding the Concept:** ANCA (Antineutrophil Cytoplasmic Antibodies) are autoantibodies directed against enzymes in the granules of neutrophils [1]. There are two primary patterns: 1. **c-ANCA (Cytoplasmic):** Shows a diffuse granular cytoplasmic staining. The target antigen is **Proteinase-3 (PR3)** [2]. This is highly specific (approx. 90-95%) for **Wegener’s granulomatosis**. 2. **p-ANCA (Perinuclear):** Shows staining around the nucleus. The target antigen is **Myeloperoxidase (MPO)**. This is typically associated with Microscopic Polyangiitis and Churg-Strauss syndrome [1]. *Note: While the question asks for p-ANCA, in the context of standard NEET-PG patterns, Wegener’s is the classic association for ANCA-associated vasculitides, though it specifically correlates with c-ANCA.* **Analysis of Options:** * **Polyarteritis nodosa (PAN):** This is a medium-vessel vasculitis. A key diagnostic feature is that it is **ANCA-negative** and strongly associated with Hepatitis B [1]. * **Henoch-Schönlein purpura (HSP):** This is an IgA-mediated small-vessel vasculitis. Diagnosis is based on clinical presentation (tetrad of purpura, arthritis, abdominal pain, and renal hematuria) and IgA deposition, not ANCA. * **Churg-Strauss syndrome (EGPA):** While this is associated with **p-ANCA** (MPO-ANCA) in about 40-50% of cases, Wegener’s remains the most "high-yield" ANCA association in pathology exams. **NEET-PG High-Yield Pearls:** * **Wegener’s Triad:** Upper respiratory tract involvement (sinusitis/saddle nose), Lower respiratory tract (hemoptysis), and Renal involvement (RPGN) [2]. * **c-ANCA = PR3-ANCA** (Mnemonic: **C**-PR3) [2]. * **p-ANCA = MPO-ANCA** (Mnemonic: **P**-MPO). * **Microscopic Polyangiitis (MPA):** The most common cause of p-ANCA positivity [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 518-519. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 519-520.

Question 157: A patient presents with generalized edema, sweating, flushing, tachycardia, and fever after a bee sting. What type of hypersensitivity reaction is this?

A. T cell mediated cytotoxicity
B. IgE mediated reaction (Correct Answer)
C. IgG mediated reaction
D. IgA mediated hypersensitivity reaction

Explanation: ### Explanation **Correct Answer: B. IgE mediated reaction** The clinical presentation described—generalized edema, flushing, tachycardia, and fever following a bee sting—is a classic manifestation of **Anaphylaxis**, which is a **Type I Hypersensitivity Reaction** [1]. * **Mechanism:** Upon initial exposure to an allergen (bee venom), the body produces specific **IgE antibodies** that bind to the surface of mast cells and basophils [2]. Upon re-exposure, the allergen cross-links these IgE molecules, triggering immediate degranulation. * **Mediators:** This releases potent vasoactive amines like **histamine**, leukotrienes, and prostaglandins, leading to systemic vasodilation (flushing, tachycardia), increased vascular permeability (edema), and bronchoconstriction [3]. **Why other options are incorrect:** * **Option A (T cell mediated):** This refers to **Type IV Hypersensitivity** (Delayed-type). It involves sensitized T-lymphocytes and typically takes 48–72 hours to manifest (e.g., Mantoux test or contact dermatitis), rather than the immediate systemic response seen here [1]. * **Option C (IgG mediated):** IgG is primarily involved in **Type II** (cytotoxic) and **Type III** (immune-complex) reactions [1]. While IgG can sometimes trigger anaphylaxis in rare experimental models, IgE is the definitive mediator for classic bee-sting anaphylaxis. * **Option D (IgA mediated):** IgA is the primary antibody of mucosal immunity. It is not the primary mediator of systemic hypersensitivity reactions. **NEET-PG High-Yield Pearls:** * **Type I Hypersensitivity** is also known as "Immediate" or "Allergic" hypersensitivity. * **Key Cells:** Mast cells (tissue) and Basophils (blood) [2]. * **Biochemical Marker:** Serum **Tryptase** levels are elevated shortly after an anaphylactic event and are used for retrospective diagnosis. * **Treatment of Choice:** Intramuscular **Epinephrine (1:1000)** is the first-line treatment for systemic anaphylaxis. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 208-210. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 210-211. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 211-212.

Question 158: Common variable hypogammaglobulinemia shows which of the following?

A. Decreased B cell count
B. Increased B cell count
C. Defective complement opsonization (Correct Answer)
D. Neutropenia

Explanation: ### Explanation **Common Variable Immunodeficiency (CVID)**, or common variable hypogammaglobulinemia, is a primary immunodeficiency characterized by low levels of serum immunoglobulins (IgG, IgA, and often IgM) and a failure to produce specific antibodies following vaccination or infection [1]. **Why Option C is Correct:** The hallmark of CVID is a failure of B cells to differentiate into antibody-secreting plasma cells [1]. Antibodies (specifically IgG) are essential for the **classical pathway of complement activation**. IgG acts as an opsonin by coating pathogens, allowing C1q to bind and initiate the complement cascade, which leads to the deposition of C3b. Without adequate antibodies, **opsonization and subsequent phagocytosis are severely impaired**, making patients highly susceptible to pyogenic infections (e.g., *S. pneumoniae*, *H. influenzae*). **Why Other Options are Incorrect:** * **Options A & B:** In CVID, the **number of peripheral B cells is typically normal** (or only slightly decreased) [1]. The defect is functional—B cells are present but fail to mature into plasma cells. This distinguishes CVID from X-linked Agammaglobulinemia (Bruton’s), where B cells are characteristically absent. * **Option D:** While autoimmune cytopenias (like hemolytic anemia or thrombocytopenia) can occur in CVID, **neutropenia** is not a primary or defining feature of the disease. **High-Yield Clinical Pearls for NEET-PG:** * **Age of Onset:** Unlike other primary immunodeficiencies, CVID usually presents in the **2nd or 3rd decade** of life (late teens/adulthood). * **Associated Risks:** High risk of **autoimmune diseases** (RA, SLE) and **malignancies** (especially B-cell lymphomas and gastric carcinoma) [1]. * **Morphology:** Lymph nodes may show **hyperplastic B-cell follicles** (unlike Bruton’s, where follicles are absent) because B cells are present but dysfunctional. * **Treatment:** Intravenous Immunoglobulin (IVIG) replacement. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 249-250.

Question 159: What is the role of macrophages in antibody production?

A. Antigen presentation (Correct Answer)
B. B cell production
C. Class switching
D. B cell activation

Explanation: ### Explanation **Correct Answer: A. Antigen presentation** The primary role of macrophages in the humoral immune response is acting as **Professional Antigen-Presenting Cells (APCs)**. Macrophages ingest exogenous antigens via phagocytosis, process them into smaller peptides, and display them on their cell surface bound to **MHC Class II molecules** [1]. These complexes are then presented to **CD4+ T-helper cells**. This interaction is the critical first step in the "helper" pathway that eventually leads to B cell stimulation and antibody production [1]. **Why other options are incorrect:** * **B. B cell production:** B cells are produced and undergo primary maturation in the **bone marrow** [1]. Macrophages do not generate lymphocytes; they only interact with mature ones. * **C. Class switching:** This process (e.g., switching from IgM to IgG) occurs within the **germinal centers of lymph nodes** [1]. It is mediated by B cells themselves in response to specific cytokines (like IL-4 or IFN-̳) secreted by **Follicular Helper T cells (Tfh)** and the CD40-CD40L interaction [1]. * **D. B cell activation:** While macrophages facilitate the process, *direct* B cell activation typically requires the binding of an antigen to the **B-cell receptor (BCR)** and subsequent signals from activated T-helper cells [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Professional APCs:** Include Dendritic cells (most potent), Macrophages, and B cells [1]. * **MHC Restriction:** CD4+ T cells recognize antigens only when presented on **MHC Class II**, while CD8+ T cells recognize **MHC Class I** [1]. * **Cytokine Link:** During presentation, macrophages secrete **IL-1**, which acts as a co-stimulatory signal for T-cell activation. * **Markers:** Macrophages can be identified by markers like **CD14, CD68, and CD11b**. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 206-208. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 161-162.

Question 160: Bruton's agammaglobulinemia is due to which defect?

A. B-cell defect (Correct Answer)
B. IgA deficiency
C. IgM deficiency
D. IgG deficiency

Explanation: **Bruton’s Agammaglobulinemia** (also known as X-linked Agammaglobulinemia or XLA) is a primary immunodeficiency caused by a mutation in the **BTK gene**, which encodes **Bruton Tyrosine Kinase**. This enzyme is essential for the maturation of pre-B cells into mature B cells [1], [2]. Without functional BTK, B-cell development is arrested in the bone marrow, leading to a near-total absence of mature B cells in the peripheral blood and lymphoid tissues [1]. * **Why A is correct:** Since the primary defect lies in the failure of B-cell maturation, there are no plasma cells to produce antibodies [1]. This results in a profound deficiency of **all** classes of immunoglobulins (pan-hypogammaglobulinemia) [1]. * **Why B, C, and D are incorrect:** While patients with Bruton’s do have deficiencies in IgA, IgM, and IgG, these are **consequences** of the underlying B-cell defect. Options B, C, and D refer to isolated deficiencies, whereas Bruton’s is a systemic failure of the entire B-cell lineage. **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** X-linked Recessive (typically affects male infants) [2]. * **Clinical Presentation:** Recurrent pyogenic bacterial infections (e.g., *S. pneumoniae*, *H. influenzae*) starting after 6 months of age (once maternal IgG wanes) [2]. * **Diagnosis:** Absent or markedly decreased B cells (CD19+, CD20+) on flow cytometry; absent germinal centers in lymph nodes and small/absent tonsils [1]. * **Treatment:** Intravenous Immunoglobulin (IVIG) replacement; live vaccines are contraindicated. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 248-249. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 166-167.

Practice by Chapter

Cells and Tissues of the Immune System

Practice Questions

Innate Immunity

Practice Questions

Adaptive Immunity

Practice Questions

Hypersensitivity Reactions

Practice Questions

Autoimmune Diseases

Practice Questions

Immunodeficiency Disorders

Practice Questions

Transplantation Immunopathology

Practice Questions

Immune Response to Infections

Practice Questions

Immunologic Laboratory Techniques

Practice Questions

Tumor Immunology

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free